Browse > Article
http://dx.doi.org/10.3857/roj.2017.00115

Prognostic value of nodal SUVmax of 18F-FDG PET/CT in nasopharyngeal carcinoma treated with intensity-modulated radiotherapy  

Lee, So Jung (Department of Radiation Oncology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea)
Kay, Chul-Seoung (Department of Radiation Oncology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea)
Kim, Yeon-Sil (Department of Radiation Oncology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea)
Son, Seok Hyun (Department of Radiation Oncology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea)
Kim, Myungsoo (Department of Radiation Oncology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea)
Lee, Sea-Won (Department of Radiation Oncology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea)
Kang, Hye Jin (Department of Radiation Oncology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea)
Publication Information
Radiation Oncology Journal / v.35, no.4, 2017 , pp. 306-316 More about this Journal
Abstract
Purpose: To investigate the predictive role of maximum standardized uptake value ($SUV_{max}$) of 2-[$^{18}F$]fluoro-2-deoxy-D-glucose($^{18}F-FDG$) positron emission tomography/computed tomography (PET/CT) in nasopharyngeal cancer patients treated with intensity-modulated radiotherapy (IMRT). Materials and Methods: Between October 2006 and April 2016, 53 patients were treated with IMRT in two institutions and their PET/CT at the time of diagnosis was reviewed. The $SUV_{max}$ of their nasopharyngeal lesions and metastatic lymph nodes (LN) was recorded. IMRT was delivered using helical tomotherapy. All patients except for one were treated with concurrent chemoradiation therapy (CCRT). Correlations between $SUV_{max}$ and patients' survival and recurrence were analyzed. Results: At a median follow-up time of 31.5 months (range, 3.4 to 98.7 months), the 3-year overall survival (OS) and disease-free survival (DFS) rates were 83.2% and 77.5%, respectively. In univariate analysis, patients with a higher nodal pre-treatment $SUV_{max}$ (${\geq}13.4$) demonstrated significantly lower 3-year OS (93.1% vs. 55.5%; p = 0.003), DFS (92.7% vs. 38.5%; p < 0.001), locoregional recurrence-free survival (100% vs. 50.5%; p < 0.001), and distant metastasis-free survival (100% vs. 69.2%; p = 0.004), respectively. In multivariate analysis, high pre-treatment nodal $SUV_{max}$ (${\geq}13.4$) was a negative prognostic factor for OS (hazard ratio [HR], 7.799; 95% confidence interval [CI], 1.506-40.397; p = 0.014) and DFS (HR, 9.392; 95% CI, 1.989-44.339; p = 0.005). Conclusions: High pre-treatment nodal $SUV_{max}$ was an independent prognosticator of survival and disease progression in nasopharyngeal carcinoma patients treated with IMRT in our cohort. Therefore, nodal $SUV_{max}$ may provide important information for identifying patients who require more aggressive treatment.
Keywords
Nasopharyngeal carcinoma; $SUV_{max}$; Prognostic factor;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Yoon YH, Lee SH, Hong SL, Kim SJ, Roh HJ, Cho KS. Prognostic value of metabolic tumor volume as measured by fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in nasopharyngeal carcinoma. Int Forum Allergy Rhinol 2014;4:845-50.   DOI
2 Chan SC, Hsu CL, Yen TC, Ng SH, Liao CT, Wang HM. The role of 18F-FDG PET/CT metabolic tumour volume in predicting survival in patients with metastatic nasopharyngeal carcinoma. Oral Oncol 2013;49:71-8.   DOI
3 Moon SH, Choi JY, Lee HJ, et al. Prognostic value of volumebased positron emission tomography/computed tomography in patients with nasopharyngeal carcinoma treated with concurrent chemoradiotherapy. Clin Exp Otorhinolaryngol 2015;8:142-8.   DOI
4 Lin J, Xie G, Liao G, et al. Prognostic value of 18F-FDG-PET/CT in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis. Oncotarget 2017;8:33884-96.
5 Qiu WZ, Huang PY, Shi JL, Xia HQ, Zhao C, Cao KJ. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study. Chin J Cancer 2016;35:2.   DOI
6 Chi KH, Chang YC, Guo WY, et al. A phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys 2002;52:1238-44.   DOI
7 Chen L, Hu CS, Chen XZ, et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol 2012;13:163-71.   DOI
8 Vansteenkiste JF, Stroobants SG, Dupont PJ, et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in nonsmall-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol 1999;17:3201-6.   DOI
9 Guo Q, Lu T, Lin S, et al. Long-term survival of nasopharyngeal carcinoma patients with Stage II in intensity-modulated radiation therapy era. Jpn J Clin Oncol 2016;46:241-7.   DOI
10 Zhao W, Lei H, Zhu X, Li L, Qu S, Liang X. Investigation of long-term survival outcomes and failure patterns of patients with nasopharyngeal carcinoma receiving intensitymodulated radiotherapy: a retrospective analysis. Oncotarget 2016;7:86914-25.
11 Luo Y, Gao Y, Yang G, Lang J. Clinical outcome and prognostic factors of intensity-modulated radiotherapy for T4 stage nasopharyngeal carcinoma. Biomed Res Int 2016;2016:4398498.
12 Xie P, Yue JB, Fu Z, Feng R, Yu JM. Prognostic value of 18F-FDG PET/CT before and after radiotherapy for locally advanced nasopharyngeal carcinoma. Ann Oncol 2010;21:1078-82.   DOI
13 Oshida M, Uno K, Suzuki M, et al. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F]-D-glucose. Cancer 1998;82:2227-34.   DOI
14 Lee SW, Nam SY, Im KC, et al. Prediction of prognosis using standardized uptake value of 2-[(18)F] fluoro-2-deoxy-dglucose positron emission tomography for nasopharyngeal carcinomas. Radiother Oncol 2008;87:211-6.   DOI
15 Chan SC, Chang JT, Wang HM, et al. Prediction for distant failure in patients with stage M0 nasopharyngeal carcinoma: the role of standardized uptake value. Oral Oncol 2009;45:52-8.   DOI
16 Zhang J, Shu C, Song Y, Li Q, Huang J, Ma X. Epstein-Barr virus DNA level as a novel prognostic factor in nasopharyngeal carcinoma: a meta-analysis. Medicine (Baltimore) 2016;95:e5130.   DOI
17 Liu WS, Wu MF, Tseng HC, et al. The role of pretreatment FDG-PET in nasopharyngeal carcinoma treated with intensitymodulated radiotherapy. Int J Radiat Oncol Biol Phys 2012;82:561-6.   DOI
18 Chan WK, Kwong DL, Yeung DW, Huang B, Khong PL. Prognostic impact of standardized uptake value of F-18 FDG PET/CT in nasopharyngeal carcinoma. Clin Nucl Med 2011;36:1007-11.   DOI
19 Xiao W, Xu A, Han F, et al. Positron emission tomographycomputed tomography before treatment is highly prognostic of distant metastasis in nasopharyngeal carcinoma patients after intensity-modulated radiotherapy treatment: a prospective study with long-term follow-up. Oral Oncol 2015;51:363-9.   DOI
20 Jeong Y, Baek S, Park JW, Joo JH, Kim JS, Lee SW. Lymph node standardized uptake values at pre-treatment (18) F-fluorodeoxyglucose positron emission tomography as a valuable prognostic factor for distant metastasis in nasopharyngeal carcinoma. Br J Radiol 2017;90:20160239.   DOI
21 Hui EP, Ma BB, Chan KC, et al. Clinical utility of plasma Epstein-Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma. Cancer 2015;121:2720-9.   DOI
22 Chua MLK, Wee JTS, Hui EP, Chan ATC. Nasopharyngeal carcinoma. Lancet 2016;387:1012-24.   DOI
23 Chan SC, Chang JT, Lin CY, et al. Clinical utility of 18F-FDG PET parameters in patients with advanced nasopharyngeal carcinoma: predictive role for different survival endpoints and impact on prognostic stratification. Nucl Med Commun 2011;32:989-96.   DOI
24 Inokuchi H, Kodaira T, Tachibana H, et al. Clinical usefulness of [18F] fluoro-2-deoxy-D-glucose uptake in 178 head-and-neck cancer patients with nodal metastasis treated with definitive chemoradiotherapy: consideration of its prognostic value and ability to provide guidance for optimal selection of patients for planned neck dissection. Int J Radiat Oncol Biol Phys 2011;79:747-55.   DOI
25 Yang Z, Shi Q, Zhang Y, et al. Pretreatment (18)F-FDG uptake heterogeneity can predict survival in patients with locally advanced nasopharyngeal carcinoma: a retrospective study. Radiat Oncol 2015;10:4.   DOI